As shareholders we have better insight into the pr
Post# of 36537
(Total Views: 184)
Posted On: 10/18/2019 10:35:26 AM
As shareholders we have better insight into the process and priorities.
Priorities:
10K, S1,Uplisting to NASDAQ, and the Spinout (NGIO?)
Process:
What requirements are necessary for a company that is relisting to NASDAQ (Generex) compared to a company that has never been listed?
In relisting, if a company with a history on NASDAQ exceeds its requirements for shareholder count, board lots, and other major areas of compliance, what is the impact of failing to meet the $2 pricing rule?
That's my interpretation, and I think it lends some clarity to the situation. However, there are questions that need to be answered by Donohoe and NASDAQ. Comments?
Priorities:
10K, S1,Uplisting to NASDAQ, and the Spinout (NGIO?)
Process:
What requirements are necessary for a company that is relisting to NASDAQ (Generex) compared to a company that has never been listed?
In relisting, if a company with a history on NASDAQ exceeds its requirements for shareholder count, board lots, and other major areas of compliance, what is the impact of failing to meet the $2 pricing rule?
That's my interpretation, and I think it lends some clarity to the situation. However, there are questions that need to be answered by Donohoe and NASDAQ. Comments?
(1)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼